TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19493958
Drug: modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: modafinil (300 mg) and prazosin (3 mg) together
Study: 12815555
Drug: Oxymetholone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetholone (50 mg bid)
Study: 12815555
Drug: Oxymetholone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetholone (50 mg tid)
Study: 24570989
Drug: Machined neck
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined neck implants (group 1)
Study: 24570989
Drug: Rough, grooved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough, grooved neck implants (group 2)
Study: 12372132
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg Fexofenadine (FEX)
Study: 12372132
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Desloratadine (DL)
Study: 10535855
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CSA) to achieve whole blood trough levels of 120‐150 ng/ml
Study: 2187169
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg b.i.d. IM from the day before operation to the 7th postoperative day, n = 60)
Study: 2187169
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5000 IU t.i.d. SC from the operation to the 7th postoperative day, n = 70)
Study: 31866211
Drug: Health for
Normalized name: Eye Health Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health for Hearts United intervention (3 treatment churches)
Study: 19242485
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid and oral ibuprofen for 3 days
Study: 16445331
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy and 35 minutes of CPM applications daily
Study: 16445331
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy and 2 hours of CPM applications daily
Study: 15540744
Drug: Transdermal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal laser stimulation of the posterior tibial nerve, performed daily for 30 seconds over the SP6 acupuncture point for 12 weeks
Study: 11236073
Drug: Mirtazapine add
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine add on therapy to haloperidol 5 mg
Study: 11236073
Drug: Placebo add
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add on therapy to haloperidol 5 mg
Study: 9286889
Drug: DDAVP (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.3 microg/kg in 100 ml normal saline)
Study: 8361794
Drug: High-iron content
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-iron content premature formula (15 mg/L)
Study: 8361794
Drug: Low-iron content
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron content premature formula (3 mg/L)
Study: 8361794
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk mixed with liquid fortifier (1.7 mg/L)
Study: 3731212
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg loading dose on day 1, 4 mg/kg/day for 3 days)
Study: 3731212
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aminophylline treatment)
Study: 23656848
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg/d)
Study: 19812581
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 20 p.p.m. decreasing to 2 p.p.m. for 24 days
Study: 11915394
Drug: Standard injections
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injections
Study: 10396711
Drug: Ketamine 50
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 50 mg
Study: 10396711
Drug: Ketamine 100
Normalized name: ketamine 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 100 mg
Study: 10396711
Drug: Ketamine 150
Normalized name: bupivacaine/ketorolac/ketamine 150 mg-60 mg-60 mg/50 mL INJECTION SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 150 mg
Study: 10396711
Drug: Ketamine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 200 mg
Study: 7484046
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 1% prilocaine plus 6 mg morphine sulfate in 10 ml of 0.9% sodium chloride (P/M group)
Study: 7484046
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 1% prilocaine plus 10 ml of 0.9% sodium chloride (P group)
Study: 2292535
Drug: Comparative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative antibiotics
Study: 26059872
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits with a general practitioner and municipal nurse within seven days of discharge focusing on medication, rehabilitation plan, functional level, and need for further health care initiatives.
Study: 23463656
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion for 2 hours
Study: 21483704
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT), n=64
Study: 21483704
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (CBGT), n=62
Study: 17228550
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antidepressants
Study: 9007493
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU r‐HuEpo/kg, subcutaneously thrice weekly
Study: 9007493
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU r‐HuEpo/kg, subcutaneously thrice weekly
Study: 29152749
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal anesthetic (0.4 mL of 2% viscous lidocaine hydrochloride)
Study: 29152749
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal anesthetic
Study: 27503659
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg REL plus 500 mg IMI
Study: 27503659
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg REL plus 500 mg IMI
Study: 27503659
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IMI alone
Study: 20133012
Drug: Imiquimod 2.5%
Normalized name: IMIQUIMOD 2.5% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 2.5% cream
Study: 20133012
Drug: Imiquimod 3.75%
Normalized name: IMIQUIMOD 3.75% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 3.75% cream
Study: 14625812
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (3 x 3 MIU sc weekly) and oral ribavirin (1000/1200 mg po daily) for 24 weeks
Study: 14625812
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (3 x 3 MIU sc weekly) and oral ribavirin (1000/1200 mg po daily) for 48 weeks
Study: 8690831
Drug: ICI 204,636
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,636 (75 to 750 mg daily)
Study: 264798
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation combined with a 3-year course of multiple drug systemic chemotherapy
Study: 264798
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose palliative irradiation
Study: 264798
Drug: Multiple agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple agent chemotherapy and preventive meningeal irradiation
Study: 27298379
Drug: Carvedilol (12±1.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12±1.67 mg/day)
Study: 22094037
Drug: Ephedrine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (4 g/L)
Study: 22094037
Drug: Ephedrine plus
Normalized name: EPHEDRINE HYDROCHLORIDE 12.5 mg / GUAIFENESIN 200 mg ORAL TABLET [Red Label Ephedrine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine plus Phenylephrine (ephedrine 2 g/L + phenylephrine 25 mg/L)
Study: 22094037
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 mg/L)
Study: 12779280
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream (6%)
Study: 12779280
Drug: Tetracaine cream
Normalized name: BENZALKONIUM CL/BENZOCAINE/DIBUCAINE/TETRACAINE CREAM,TOP
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine cream (4%)
Study: 10684018
Drug: 0.82 g.kg‐1.d‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.82 g.kg‐1.d‐1 fat emulsion (42% of total calorie)
Study: 10684018
Drug: 1.72 g.kg‐1.d‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.72 g.kg‐1.d‐1 fat emulsion (52% of total calorie)
Study: 322634
Drug: Affect-arousing, gestalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect-arousing, gestalt therapy
Study: 29775202
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 μM with 0.05% DMSO
Study: 29775202
Drug: 0.05% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% DMSO without aspirin
Study: 26024743
Drug: Lipegfilgrastim 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipegfilgrastim 6 mg once per cycle
Study: 26024743
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg once per cycle
Study: 20105189
Drug: rs4410646 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs4410646 genotype (CC)
Study: 10570387
Drug: 1.8% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8% tetracaine cream
Study: 1816827
Drug: Collective measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collective measures of oral hygiene (monthly, quarterly, half-yearly intervals)
Study: 1816827
Drug: Twice instructed
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice instructed measures of oral hygiene
Study: 7280450
Drug: Octavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octavalent vaccine (Eli Lilly Laboratories) given at six months and/or 12 months of age
Study: 7280450
Drug: 14-valent vaccine
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent vaccine (Merck Sharp & Dohme) given at 12 months of age
Study: 30712247
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing based on genetic testing
Study: 27363396
Drug: Shakuyaku‐kanzo‐to (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shakuyaku‐kanzo‐to (2.5 g as needed)
Study: 27363396
Drug: Shakuyaku‐kanzo‐to (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shakuyaku‐kanzo‐to (7.5 g/day)
Study: 7681516
Drug: Oral dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dofetilide (5 micrograms/kg)
Study: 7681516
Drug: Oral dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dofetilide (7.5 micrograms/kg)
Study: 7681516
Drug: Oral dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dofetilide (10 micrograms/kg)
Study: 7681516
Drug: Intravenous dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dofetilide (0.5 mg)
Study: 7681516
Drug: Oral dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dofetilide (0.5 mg)
Study: 2877594
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% and 0.1 mg fentanyl (control group C)
Study: 28197979
Drug: OM3-CA 4
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA 4 g
Study: 27686403
Drug: 2% CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CAF solution
Study: 22969732
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg plus d-amphetamine 30 mg
Study: 22969732
Drug: d-amphetamine 60
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 60 mg
Study: 19112722
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg per day
Study: 19112722
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg per day
Study: 19112722
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Acetylsalicylic acid and Ibuprofen)
Study: 10209373
Drug: Prilocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 3% with felypressin 0.03 IU.ml‐1
Study: 25311998
Drug: Combination Intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Intervention Strategy (CIS) including point-of-care CD4 count testing, accelerated antiretroviral therapy initiation, SMS reminders for linkage and retention in care
Study: 25311998
Drug: Combination Intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Intervention Strategy plus Financial Incentives (CIS + FI)
Study: 20837352
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of test oil containing 27.3% DAG
Study: 20837352
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of test oil containing 54.6% DAG
Study: 16325031
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg/day for 10 days starting 2 days before repeat intervention)
Study: 7906539
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Apraclonidine 1% and Pilocarpine 4%)
Study: 2780105
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg/24 h for 7 days plus saline irrigation of the operative site.
Study: 2780105
Drug: Cefotiam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (2 g intraoperatively, 2 g at 12 hours and 24 hours post-surgery) plus Povidone iodine (5% dilution) irrigation of the operative site.
Study: 1219635
Drug: Acebutolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (600 to 800 mg)
Study: 29871185
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection with mouse nerve growth factor and methylprednisolone
Study: 29871185
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication and methylprednisolone (0.5 ml) + 0.9% NaCl (0.5 ml)
Study: 24589090
Drug: Immunonutrition (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition (oral supplementation containing arginine, ω‐3 fatty acids, and RNA for 5 days before surgery)
Study: 15655825
Drug: HCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCC vaccine group
Study: 7535669
Drug: Pirenzepine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (200 mg orally)
Study: 7535669
Drug: GH releasing
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH releasing hormone (GHRH) 1‐44 (80 micrograms i.v.)
Study: 15894
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 50 mg progesterone and 3 mg oestradiol benzoate in oil
Study: 15894
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal injection (Control)
Study: 29428088
Drug: Parenteral cobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cobalamin (0.4–1.2 mg hydroxycobalamin according to body weight)
Study: 29428088
Drug: Oral cobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cobalamin tablets (0.25–1.0 mg cyanocobalamin daily according to body weight)
Study: 24980426
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg before surgery followed by 200 mg TID for 4 days
Study: 18473407
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid)
Study: 18473407
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy (same medication as group 1)
Study: 18473407
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy
Study: 18473407
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy
Study: 12809972
Drug: Increased copayments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased copayments in 1995 and 1997 for antidepressants, anxiolytics, and sedatives
Study: 12809972
Drug: Increased copayments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased copayments in 1997 for antidepressants
Study: 1407968
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg/day
Study: 2860268
Drug: Piretanide 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 12 mg daily (n = 14)
Study: 2860268
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg daily (n = 18)
Study: 2860268
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (pindolol, metipranolol, atenolol, n = 17)
Study: 27514766
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1000 mg/d from flaxseed oil)
Study: 25522399
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (6 weeks)
Study: 19855976
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate only (25 mg, four times/week)
Study: 19855976
Drug: Tamsulosin only
Normalized name: Tamsulosin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin only (0.4 mg once daily)
Study: 19855976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sildenafil citrate and tamsulosin
Study: 18721577
Drug: iNO +
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iNO + Mil (inhalation of nitric oxide plus milrinone)
Study: 18721577
Drug: iNO (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO (inhalation of nitric oxide)
Study: 12464165
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with Alternaria extract (mean accumulated dose: 280,000 PNU)
Study: 12464165
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with Alternaria extract
Study: 1868680
Drug: Low-dose phenobarbital
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phenobarbital incorporated into methadone medication
Study: 28138179
Drug: Thiopental 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 3 mg/kg intravenously followed by an additional dose of 1 mg/kg to achieve Ramsay sedation score of 4
Study: 28138179
Drug: Ketofol (1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketofol (1:1 mixture of ketamine 10 mg/mL and propofol 10 mg/mL) at a dose of 0.5 mg/kg at 1 minute intervals to achieve Ramsay sedation score of 4
Study: 25349008
Drug: Morphine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.5 mg/kg orally)
Study: 21797891
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol infusion (50 mg%) for 3 hours
Study: 21797891
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 3 hours
Study: 15827099
Drug: octreotide-LAR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide-LAR (10 mg, n = 10 subjects)
Study: 12072674
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (250 mg/6 hrs)
Study: 12072674
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous 5% dextrose, 50 mL/6 hrs)
Study: 1325513
Drug: Spirapril (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (both doses)
Study: 30556959
Drug: Miridesap 10
Normalized name: Miridesap
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miridesap 10 mg IV infusion